|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Allergic contact dermatitis |
|
folliculitis, furunculosis, pustules, pyoderma, or vesiculation |
|
hyperesthesia |
|
numbness in fingers |
|
purpura |
|
skin atrophy |
|
skin infection, secondary |
|
stripping of epidermal layer |
|
telangiectasia |
|
Acneiform eruptions |
|
cataracts, posterior subcapsular |
|
Cushing's syndrome |
|
dermatitis, perioral |
|
ecchymosis |
|
edema |
|
gastric ulcer |
|
glaucoma, secondary |
|
hirsutism or hypertrichosis |
|
hypertension |
|
hypokalemic syndrome |
|
hypopigmentation |
|
other changes in skin pigmentation |
|
infection, aggravation of |
|
miliaria rubra |
|
protein depletion |
|
skin laceration |
|
skin maceration |
|
striae |
|
subcutaneous tissue atrophy |
|
unusual loss of hair |
|
Burning, dryness, irritation, itching, or redness of skin, mild and transient |
|
increased redness or scaling of skin lesions, mild and transient |
|
skin rash, minor and transient |
|
Stinging, mild and temporary |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Allergy to corticosteroids |
|
Infection at treatment site |
|
Skin atrophy, pre-existing |
|
Herpes simplex at treatment site |
|
Cataracts |
|
Diabetes mellitus |
|
Glaucoma |
|
Tuberculosis |
|
|
ADULT DOSE:
|
|
Topical, to the skin, one to three times a day.
Note: Some patients may be maintained with once daily applications after the initial acute symptoms subside. Once daily dosage may also be used to taper therapy before discontinuance.
|
|
MAXIMUM ADULT DOSE:
|
|
100 grams per week.
|
|
PEDIATRIC DOSE:
|
|
Dosage has not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|